Status:
COMPLETED
A Clinical Study to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.
Lead Sponsor:
Actelion
Conditions:
Pulmonary Arterial Hypertension
Chronic Thromboembolic Pulmonary Hypertension
Eligibility:
All Genders
Phase:
PHASE3
Brief Summary
The aim of the trial is to study the long-term safety of macitentan and to provide continued treatment with macitentan to patients with pulmonary arterial hypertension (PAH) and Chronic thromboembolic...
Detailed Description
The purpose of this study is to provide continued treatment with macitentan to subjects with PAH or CTEPH who participated in "parent studies" and to continue to accrue long-term safety data. The desi...
Eligibility Criteria
Inclusion
- Signed informed consent to take part in the study before any study mandated procedure.
- Participants from one of the parent studies and: a) the sponsor has decided to terminate the parent study in that country and b) the participant has completed the end of treatment (EOT) Visit of the parent study
- Women of childbearing potential are able to take part in the study if the following applies: a) Urine pregnancy test is negative at Enrollment; b) Agreement to perform monthly urine or serum pregnancy tests during the study and up to at least 30 days after the study treatment discontinuation; and c) Agreement to adhere to the planned contraception scheme from Enrollment up to at least 30 days after study treatment discontinuation
Exclusion
- Hemoglobin less than 80 gram per liter (g/L)
- Serum Aspartate aminotransferase (AST) and/or alanine aminotransferases (ALT) more than three times the upper limit of normal range
- Known and documented history of severe hepatic impairment that is Child-Pugh Class C.
- Pregnant, planning to become pregnant, or breastfeeding
- Known hypersensitivity to macitentan, its excipients, or drugs of the same class
- Planned or current treatment with another investigational treatment up to 3 months prior to Enrollment
- Any known factor or disease that may interfere with treatment compliance, study conduct, or interpretation of the results, such as drug or alcohol dependence or psychiatric disease
- Treatment with a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir)
Key Trial Info
Start Date :
April 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 27 2023
Estimated Enrollment :
151 Patients enrolled
Trial Details
Trial ID
NCT03422328
Start Date
April 5 2018
End Date
December 27 2023
Last Update
April 27 2025
Active Locations (34)
Enter a location and click search to find clinical trials sorted by distance.
1
The Republican Scientific-Practical Center ''Cardiology''
Minsk, Belarus, 220036
2
UZ Leuven
Leuven, Belgium, 3000
3
CHRU Besancon Hopital Jean Minjoz
Besançon, France, 25030
4
CHU de Bordeaux - Hospital Haut-Leveque
Bordeaux (Pessac), France, 33604